Clinical studies investigating the use of leuprorelin in Asian women with endometriosis: a review
This review of four Asian studies found that leuprorelin significantly improved endometriosis pain and quality of life but decreased hormone levels and bone density, with add-back therapy mitigating hormone reduction.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (27)
- A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review via openalex
- Advances in the management of endometriosis: an update for clinicians via openalex
- A higher prevalence of endometriosis among Asian women does not contribute to poorer IVF outcomes via openalex
- A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis via openalex
- Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: a randomized clinical trial via openalex
- Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis via openalex
- Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis via openalex
- Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis via openalex
- Endometriosis and infertility: epidemiology and evidence-based treatments via openalex
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries via openalex
- Introduction: A focus on the medical management of endometriosis via openalex
- Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome via openalex
- Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via openalex
- Minimising menopausal side effects whilst treating endometriosis and fibroids via openalex
- Molecular aspects of development and regulation of endometriosis via openalex
- Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills via openalex
- Rates of endometriosis recurrence and pregnancy 1 year after treatment with intranasal buserelin acetate (Suprecur) (a prospective study) via openalex
- [Study on leuprorelin acetate in treatment of uterine adenomyosis with infertility] via openalex
- Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain via openalex
- W2277353857 via openalex
- W1981060751 via openalex
- W2615713587 via openalex
- W1512318310 via openalex
- W1962141530 via openalex
- W2151934245 via openalex
- W2006390573 via openalex
- W2163315477 via openalex
Cited by (1)
SciLite annotations
chemicals 12
organisms 2
Source provenance
- europepmc
- last seen: 2026-10-14T06:08:39.101224+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:23:40.374240+00:00
- scilite
- last seen: 2026-05-18T04:26:01.642840+00:00